设为首页 加入收藏

TOP

Carbaglu 200 mg dispersible tablets Carglumic Acid
2015-01-12 18:24:28 来源: 作者: 【 】 浏览:461次 评论:0

For doctors

 

What is it and how is it used?

Carbaglu can help eliminating excess of hyperammonaemia (elevated ammonia level in the blood), due to the lack of a specific liver enzyme N- acetylglutamate synthase. Patients with this rare disorder are not able to eliminate nitrogen waste, which builds up after eating protein. Nitrogen waste is in the form of ammonia, which is especially toxic for the brain and leads, in severe cases, to reduced levels of consciousness and to coma.
This disorder will persist during the entire life time of the patient and therefore the need for this treatment is lifelong.

What do you have to consider before using it?

Do not take Carbaglu:
Do not take Carbaglu if you are hypersensitive (allergic) to carglumic acid or any of the other ingredients of Carbaglu.
Do not take Carbaglu during breast-feeding

Take special care with Carbaglu:
Carbaglu treatment should be initiated under the supervision of a physician experienced in the treatment of metabolic disorders.

Your doctor will test your individual responsiveness to carglumic acid before initiating any long term treatment.
The dose should be adjusted individually in order to maintain normal ammonia plasma levels.

Your doctor may prescribe supplemental arginine or restrict your protein intake.

In order to follow-up your condition and your treatment, your doctor may examine your liver, your kidneys, your heart and your blood on a regular basis.

Taking other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription

Taking Carbaglu with food and drink
Carbaglu must be taken orally before meals or feedings.
The tablets must be dispersed in a minimum of 5 to 10 ml of water and taken immediately. The suspension has a slightly acidic taste.

Pregnancy and Breast-feeding

The effects of Carbaglu on pregnancy and the unborn child are not known. Please consult your doctor for advice if you are pregnant or planning to become pregnant.
The excretion of carglumic acid into breast milk has not been studied in women. Nevertheless, as carglumic acid has been shown to be present in the milk of lactating rats with potential toxic effects for their fed pups, you should not breast feed your baby if you are taking Carbaglu.

Driving and using machines
Effects on the ability to drive and use machines are not known.

How is it used?

Always take Carbaglu exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are unsure.

The usual dose:

When the patient is in hyperammonaemic coma, Carbaglu is administered by fast push through a syringe via the tube set up and used to feed you..

If you take more Carbaglu than you should:
Ask your doctor or pharmacist for advice.

If you forget to take Carbaglu:
Do not take a double dose to make up for forgotten individual doses.

What are possible side effects?

Like all medicines, Carbaglu can have side effects.

The following side effects were reported as follows: very common (occurring in at least one in 10 patients), common (occurring in at least one in 100 patients), uncommon (occurring in at least one in1,000 patients), rare (occurring in at least one in 10,000 patients), very rare (occurring in at least one in 100,000 patients).

If you notice any side effects, please inform your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children.
Do not use after the expiry date stated on the tablet container.

Store in a refrigerator (2°C – 8°C)

After first opening of the container: do not refrigerate, do not store above 30°C.
Keep the container tightly closed in order to protect from moisture.
Write the date of opening on the tablet container. Discard 1 month after first opening.

↑ back to table of contents ↑

For doctors

What is it?

Carbaglu is a medicine that contains the active substance carglumic acid. It is available as dispersible tablets. ‘Dispersible’ means that the tablets can be dispersed (mixed) in water.

What is it used for?

Carbaglu is used for the treatment of hyperammonaemia (high blood levels of ammonia) in patients who lack an enzyme called N-acetylglutamate synthase (NAGS). This enzyme normally helps to break down ammonia. If the enzyme is not present, ammonia cannot be broken down and it builds up in the blood. The disease is extremely rare. Patients with severe complete NAGS deficiency rapidly develop high levels of ammonia in the blood soon after birth. Patients with partial NAGS deficiency (a milder form of the disease) can have symptoms at almost any time of life following a stressful event such as an infection or a viral illness.
Because the number of patients with NAGS deficiency is low, it is considered ‘rare’ and Carbaglu was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 October 2000. The medicine can only be obtained with a prescription.

How is it used?

Carbaglu treatment should be started by a doctor who has experience in treating patients with metabolic diseases. Treatment may be started as early as the first day of life. The first daily dose should be 100 mg per kilogram body weight, but up to 250 mg/kg can be used if necessary. The dose should then be adjusted to maintain normal blood ammonia levels: the daily doses usually range from 10 to 100 mg/kg. The tablets should be dispersed (mixed) in a small amount of water before being given to the patient. They can easily be broken into two equal halves. The medicine is used for the patient’s whole life.

How does it work?

People with NAGS deficiency cannot break down and excrete ammonia. When this happens, ammonia builds up in the blood. This is toxic to the body, especially the brain. Carbaglu is very similar in structure to N-acetylglutamate, which activates an enzyme that breaks down ammonia. Carbaglu therefore helps break down ammonia, reducing ammonia blood levels and its toxic effects.

How has it been studied?

Carbaglu has been studied in 20 patients, 12 of whom had NAGS deficiency and were treated for an average of about three years. The other eight patients were treated for hyperammonaemia of another cause. The company also presented information from the published literature on a further four patients treated with the active substance in Carbaglu.

What benefits has it shown during the studies?

In most patients, ammonia levels were brought back to normal after Carbaglu treatment. Patients on Carbaglu could be kept stable without a need for restrictions to the diet or the use of other medicines.

What is the risk associated?

The most common side effect with Carbaglu (seen in between 1 and 10 patients in 100) is increased sweating. For the full list of side effects reported with Carbaglu, see the Package Leaflet. Carbaglu should not be used in people who may be hypersensitive (allergic) to carglumic acid or any of the other ingredients.

Why has it been approved?

NAGS deficiency is a rare, serious disease, with potentially devastating consequences and for which there are no other similar treatments. On the basis of the limited information on effectiveness and safety that was submitted, the Committee for Medicinal Products for Human Use (CHMP) concluded that Carbaglu was effective in reducing blood ammonia to normal levels. The Committee decided that Carbaglu’s benefits are greater than its risks for the treatment of hyperammonaemia due to NAGS deficiency. The Committee recommended that Carbaglu be given marketing authorisation. Carbaglu was originally authorised under ‘Exceptional Circumstances’, because, as the disease is rare, it had not been possible to obtain complete information on the medicine. As the company had supplied the additional information requested, the ‘Exceptional Circumstances’ ended on 26 June 2006.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union for Carbaglu to Orphan Europe on 24 January 2003. The marketing authorisation was renewed on 24 January 2008.

The record of Carbaglu’s designation as an orphan medicine is available here.

↑ back to table of contents ↑
 

Name

 

Carbaglu 200 mg dispersible tablets

 

Composition

Each tablet contains 200 mg of carglumic acid.

For a full list of excipients, see section 6.1

Pharmaceutical Form

Dispersible tablet
The tablets are white and elongated with three score marks and engraved on one side. The tablet can be divided into equal halves.

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Carbaglu 200 mg compresse dispe.. 下一篇Propycil® 50

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位